ATA Guidelines Tools

Adults with Differentiated THyroid Cancer - 2025 Update

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/1540959

Contents of this Issue

Navigation

Page 25 of 49

Treatment 26 Recommendation 78 A. In RAIR DTC patients with symptomatic and/or multiple bone metastases, treatment with a bone modifying agent is recommended to decrease the risk of skeletal-related events. (S-L) B. A bone-modifying agent dosing schedule of every 3 months may be considered due to a reduction in the risk of adverse events, especially osteonecrosis of the jaw, compared to monthly dosing, but may increase the risk of symptomatic skeletal events. (C-L) Recommendation 79 A. Resection and/or stereotactic body radiotherapy (SBRT) are the mainstays of therapy for central nervous system metastases. (C-L) B. RAI can be considered if central nervous system metastases concentrate RAI. If RAI is planned, SBRT and concomitant glucocorticoid therapy are recommended prior to RAI therapy to minimize the effects of a potential TSH induced increase in tumor size and RAI induced inflammatory response. (GPS) Recommendation 80 ➤ Patients should be counseled to consider enrolling in prospective clinical trials based upon specific eligibility requirements for given studies and the likelihood that the patient will benefit from participation. Clinicians considering referral of patients for trials should review available treatment options and eligibility criteria, preferably through discussions with personnel at the trial center and review of materials at the website www.clinicaltrials.gov. (GPS) Considerations Managing Pregnant Patients With DTC Recommendation 81 A. In most pregnant patients, surgery can be safely delayed until after delivery. Exceptions include rare patients for whom there is concern for significant disease progression. If necessary, surgery may be performed in the second trimester of pregnancy. (C-L) B. For pregnant patients diagnosed with DTC during pregnancy, monitoring with neck ultrasound at least once in early second trimester and more often if clinically indicated is appropriate. Cross- sectional imaging using MRI may be performed in selected cases. Imaging modalities that require ionizing radiation should not be performed other than in exceptional circumstances. (C-L)

Articles in this issue

Links on this page

Archives of this issue

view archives of ATA Guidelines Tools - Adults with Differentiated THyroid Cancer - 2025 Update